The Peptidoglycan-associated lipoprotein Pal contributes to the virulence of Burkholderia mallei and provides protection against lethal aerosol challenge

References

• Khan I, Wieler LH, Melzer F, et al. Glanders in animals: a review on epidemiology, clinical presentation, diagnosis and countermeasures. Transbound Emerg Dis. 2013;60(3):204–221.
   PubMed Web of Science ®Google Scholar
• Kettle AN, Wernery U. Glanders and the risk for its introduction through the international movement of horses. Equine Vet J. 2016;48(5):654–658.
   PubMed Web of Science ®Google Scholar
• Carr-Gregory B, Waag DM. Glanders. In: Dembek ZF, editor. Medical aspects of biological warfare. Borden Institute, Office of the Surgeon General, AMEDD Center and School, Texas, US; 2007. p. 121–146.
   Google Scholar
• Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. Nat Rev Dis Primers. 2018;4:17107.
   PubMed Web of Science ®Google Scholar
• Perumal Samy R, Stiles BG, Sethi G, et al. Melioidosis: clinical impact and public health threat in the tropics. PLoS Negl Trop Dis. 2017;11(5):e0004738.
   PubMed Web of Science ®Google Scholar
• Limmathurotsakul D, Golding N, Dance DA, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016;1:1.
   Web of Science ®Google Scholar
• Losada L, Ronning CM, DeShazer D, et al. Continuing evolution of Burkholderia mallei through genome reduction and large-scale rearrangements. Genome Biol Evol. 2010;2:102–116.
   PubMed Web of Science ®Google Scholar
• Song H, Hwang J, Yi H, et al. The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog. 2010;6(5):e1000922.
   PubMed Web of Science ®Google Scholar
• Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2004;101(39):14240–14245.
   PubMed Web of Science ®Google Scholar
• Nierman WC, DeShazer D, Kim HS, et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A. 2004;101(39):14246–14251.
   PubMed Web of Science ®Google Scholar
• Van Zandt KE, Greer MT, Gelhaus HC. Glanders: an overview of infection in humans. Orphanet J Rare Dis. 2013;8:131.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035–1044.
   PubMed Web of Science ®Google Scholar
• Stone JK, DeShazer D, Brett PJ, et al. Melioidosis: molecular aspects of pathogenesis. Expert Rev Anti Infect Ther. 2014;12(12):1487–1499.
   PubMed Web of Science ®Google Scholar
• Galyov EE, Brett PJ, Deshazer D. Molecular Insights into Burkholderia pseudomallei and Burkholderia mallei Pathogenesis. Annu Rev Microbiol. 2010;64:495–517.
   PubMed Web of Science ®Google Scholar
• David J, Bell RE, Clark GC. Mechanisms of disease: host-pathogen interactions between Burkholderia species and lung epithelial cells. Front Cell Infect Microbiol. 2015;5:80.
   PubMed Web of Science ®Google Scholar
• Hatcher CL, Muruato LA, Torres AG. Recent advances in Burkholderia mallei and B. pseudomallei research. Curr Trop Med Rep. 2015;2(2):62–69.
   PubMedGoogle Scholar
• Lipsitz R, Garges S, Aurigemma R, et al. Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis. 2012;18(12):e2-e2. online report.
   PubMedGoogle Scholar
• Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Updat. 2016;28:82–90.
   PubMed Web of Science ®Google Scholar
• Zimmerman SM, Dyke JS, Jelesijevic TP, et al. Antibodies against in vivo-expressed antigens are sufficient to protect against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei. Infect Immun. 2017;85:8.
   Web of Science ®Google Scholar
• Khakhum N, Bharaj P, Myers JN, et al. Evaluation of Burkholderia mallei Deltaton B Deltahcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis. PLoS Negl Trop Dis. 2019;13(7):e0007578.
   PubMed Web of Science ®Google Scholar
• Norris MH, Khan MSR, Chirakul S, et al. Outer membrane vesicle vaccines from biosafe surrogates prevent acute lethal glanders in mice. Vaccines (Basel). 2018;6:1.
   Web of Science ®Google Scholar
• Baker SM, Davitt CJH, Motyka N, et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides cross protection against inhalational glanders in mice and non-human primates. Vaccines (Basel). 2017;5:4.
   Web of Science ®Google Scholar
• Torres AG, Gregory AE, Hatcher CL, et al. Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine. Vaccine. 2015;33(5):686–692.
   PubMed Web of Science ®Google Scholar
• Gregory AE, Judy BM, Qazi O, et al. A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine. 2015;11(2):447–456.
   PubMed Web of Science ®Google Scholar
• Felgner PL, Kayala MA, Vigil A, et al. A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci U S A. 2009;106(32):13499–13504.
   PubMed Web of Science ®Google Scholar
• Suwannasaen D, Mahawantung J, Chaowagul W, et al. Human immune responses to Burkholderia pseudomallei characterized by protein microarray analysis. J Infect Dis. 2011;203(7):1002–1011.
   PubMed Web of Science ®Google Scholar
• Varga JJ, Vigil A, DeShazer D, et al. Distinct human antibody response to the biological warfare agent Burkholderia mallei. Virulence. 2012;3(6):510–514.
   PubMed Web of Science ®Google Scholar
• Su YC, Wan KL, Mohamed R, et al. A genome level survey of Burkholderia pseudomallei immunome expressed during human infection. Microbes Infect. 2008;10(12–13):1335–1345.
   PubMed Web of Science ®Google Scholar
• Hara Y, Mohamed R, Nathan S. Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets. PLoS One. 2009;4(8):e6496.
   PubMed Web of Science ®Google Scholar
• Champion OL, Gourlay LJ, Scott AE, et al. Immunisation with proteins expressed during chronic murine melioidosis provides enhanced protection against disease. Vaccine. 2016;34(14):1665–1671.
   PubMed Web of Science ®Google Scholar
• Gourlay LJ, Peri C, Ferrer-Navarro M, et al. Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology. Chem Biol. 2013;20(9):1147–1156.
   PubMedGoogle Scholar
• Godlewska R, Wisniewska K, Pietras Z, et al. Peptidoglycan-associated lipoprotein (Pal) of gram-negative bacteria: function, structure, role in pathogenesis and potential application in immunoprophylaxis. FEMS Microbiol Lett. 2009;298(1):1–11.
   PubMed Web of Science ®Google Scholar
• Duche D, Similarities HL. Differences between colicin and filamentous phage uptake by bacterial cells. EcoSal Plus. 2019;8:2.
   Google Scholar
• Simon R, Priefer U, Puhler A. A broad host range mobilisation system for in vivo genetic engineering: transposon mutagenesis in gram-negative bacteria. Bio/Technology. 1983;1:784–791.
   Web of Science ®Google Scholar
• Skorupski K, Taylor RK. Positive selection vectors for allelic exchange. Gene. 1996;169(1):47–52.
   PubMed Web of Science ®Google Scholar
• Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor Laboratory Press, New York, USA; 2001.
   Google Scholar
• Balder R, Lipski S, Lazarus JJ, et al. Identification of Burkholderia mallei and Burkholderia pseudomallei adhesins for human respiratory epithelial cells. BMC Microbiol. 2010;10:250.
   PubMed Web of Science ®Google Scholar
• Burtnick M, Bolton A, Brett P, et al. Identification of the acid phosphatase (acpA) gene homologues in pathogenic and non-pathogenic Burkholderia spp. facilitates TnphoA mutagenesis. Microbiology. 2001;147(Pt 1):111–120.
   PubMedGoogle Scholar
• He B, Paterson RG, Ward CD, et al. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology. 1997;237(2):249–260.
   PubMed Web of Science ®Google Scholar
• Chen Z, Gupta T, Xu P, et al. Efficacy of parainfluenza virus 5 (PIV5)-based tuberculosis vaccines in mice. Vaccine. 2015;33(51):7217–7224.
   PubMed Web of Science ®Google Scholar
• Lafontaine ER, Chen Z, Huertas-Diaz MC, et al. The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei. Vaccine: X. 2019;13:100002.
   Google Scholar
• Lafontaine ER, Zimmerman SM, Shaffer TL, et al. Use of a safe, reproducible, and rapid aerosol delivery method to study infection by Burkholderia pseudomallei and Burkholderia mallei in mice. PLoS One. 2013;8(10):e76804.
   PubMed Web of Science ®Google Scholar
• Zimmerman SM, Michel F, Hogan RJ, et al. The autotransporter BpaB contributes to the virulence of Burkholderia mallei in an aerosol model of infection. PLoS One. 2015;10(5):e0126437.
   PubMed Web of Science ®Google Scholar
• Bullard B, Lipski SL, Lafontaine ER. Hag directly mediates the adherence of Moraxella catarrhalis to human middle ear cells. Infect Immun. 2005;73(8):5127–5136.
   PubMed Web of Science ®Google Scholar
• Lafontaine ER, Balder R, Michel F, et al. Characterization of an autotransporter adhesin protein shared by Burkholderia mallei and Burkholderia pseudomallei. BMC Microbiol. 2014;14:92.
   PubMed Web of Science ®Google Scholar
• Aschenbroich SA, Lafontaine ER, Lopez MC, et al. Transcriptome analysis of human monocytic cells infected with Burkholderia species and exploration of pentraxin-3 as part of the innate immune response against the organisms. BMC Med Genomics. 2019;12(1):127.
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench H. A simple method for estimating fifty percent end points. Am J Hyg. 1938;27:793–797.
   Google Scholar
• Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30(2):557–596.
   PubMed Web of Science ®Google Scholar
• Willcocks SJ, Denman CC, Atkins HS, et al. Intracellular replication of the well-armed pathogen Burkholderia pseudomallei. Curr Opin Microbiol. 2016;29:94–103.
   PubMed Web of Science ®Google Scholar
• Aschenbroich SA, Lafontaine ER, Hogan RJ. Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches. Expert Rev Vaccines. 2016;(9):1–19.
   Web of Science ®Google Scholar
• Burtnick MN, Brett PJ, Woods DE. Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol. 2002;184(3):849–852.
   PubMed Web of Science ®Google Scholar
• Larsen JC, Johnson NH. Pathogenesis of Burkholderia pseudomallei and Burkholderia mallei. Mil Med. 2009;174(6):647–651.
   PubMed Web of Science ®Google Scholar
• Chen Z. Parainfluenza virus 5-vectored vaccines against human and animal infectious diseases. Rev Med Virol. 2018;28:2.
   Web of Science ®Google Scholar
• Schell MA, Zhao P, Wells L. Outer membrane proteome of Burkholderia pseudomallei and Burkholderia mallei from diverse growth conditions. J Proteome Res. 2011;10(5):2417–2424.
   PubMed Web of Science ®Google Scholar
• Michel LV, Shaw D, Hellman J, et al. Dual orientation of the outer membrane lipoprotein Pal in Escherichia coli. Microbiology. 2015;161(6):1251–1259.
   PubMedGoogle Scholar
• Murphy TF, Kirkham C, Lesse AJ. Construction of a mutant and characterization of the role of the vaccine antigen P6 in outer membrane integrity of nontypeable Haemophilus influenzae. Infect Immun. 2006;74(9):5169–5176.
   PubMed Web of Science ®Google Scholar
• Dubuisson JF, Vianney A, Hugouvieux-Cotte-Pattat N, et al. Tol-Pal proteins are critical cell envelope components of Erwinia chrysanthemi affecting cell morphology and virulence. Microbiology. 2005;151(Pt 10):3337–3347.
   PubMedGoogle Scholar
• Lim A Jr., De Vos D, Brauns M, et al. Molecular and immunological characterization of OprL, the 18 kDa outer-membrane peptidoglycan-associated lipoprotein (PAL) of Pseudomonas aeruginosa. Microbiology. 1997;143(Pt 5):1709–1716.
   PubMedGoogle Scholar
• Fortney KR, Young RS, Bauer ME, et al. Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of Haemophilus ducreyi infection. Infect Immun. 2000;68(11):6441–6448.
   PubMed Web of Science ®Google Scholar
• Hsieh PF, Liu JY, Pan YJ, et al. Klebsiella pneumoniae peptidoglycan-associated lipoprotein and murein lipoprotein contribute to serum resistance, antiphagocytosis, and proinflammatory cytokine stimulation. J Infect Dis. 2013;208(10):1580–1589.
   PubMed Web of Science ®Google Scholar
• Dennehy R, Romano M, Ruggiero A, et al. The Burkholderia cenocepacia peptidoglycan-associated lipoprotein is involved in epithelial cell attachment and elicitation of inflammation. Cell Microbiol. 2017;19:5.
   Web of Science ®Google Scholar
• Cao L, Lim T, Jun S, et al. Vulnerabilities in Yersinia pestis caf operon are unveiled by a salmonella vector. PLoS One. 2012;7(4):e36283.
   PubMed Web of Science ®Google Scholar
• Yang X, Thornburg T, Suo Z, et al. Flagella overexpression attenuates Salmonella pathogenesis. PLoS One. 2012;7(10):e46828.
   PubMed Web of Science ®Google Scholar
• Lei L, Yang F, Zou J, et al. DNA vaccine encoding OmpA and Pal from Acinetobacter baumannii efficiently protects mice against pulmonary infection. Mol Biol Rep. 2019;46(5):5397–5408.
   Web of Science ®Google Scholar
• Mobarez AM, Rajabi RA, Salmanian AH, et al. Induction of protective immunity by recombinant peptidoglycan associated lipoprotein (rPAL) protein of Legionella pneumophila in a BALB/c mouse model. Microb Pathog. 2019;128:100–105.
   PubMed Web of Science ®Google Scholar
• Green BA, Quinn-Dey T, Zlotnick GW. Biologic activities of antibody to a peptidoglycan-associated lipoprotein of Haemophilus influenzae against multiple clinical isolates of H. influenzae type b. Infect Immun. 1987;55(12):2878–2883.
   PubMed Web of Science ®Google Scholar
• Yang YP, Munson RS Jr., Grass S, et al. Effect of lipid modification on the physicochemical, structural, antigenic and immunoprotective properties of Haemophilus influenzae outer membrane protein P6. Vaccine. 1997;15(9):976–987.
   PubMed Web of Science ®Google Scholar
• Kyd JM, Dunkley ML, Cripps AW. Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun. 1995;63(8):2931–2940.
   PubMed Web of Science ®Google Scholar
• DeMaria TF, Murwin DM, Leake ER. Immunization with outer membrane protein P6 from nontypeable Haemophilus influenzae induces bactericidal antibody and affords protection in the chinchilla model of otitis media. Infect Immun. 1996;64(12):5187–5192.
   PubMed Web of Science ®Google Scholar
• Green BA, Vazquez ME, Zlotnick GW, et al. Evaluation of mixtures of purified Haemophilus influenzae outer membrane proteins in protection against challenge with nontypeable H. influenzae in the chinchilla otitis media model. Infect Immun. 1993;61(5):1950–1957.
   PubMed Web of Science ®Google Scholar
• Sabirov A, Kodama S, Hirano T, et al. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun. 2001;69(5):2964–2971.
   PubMed Web of Science ®Google Scholar
• Hotomi M, Yamanaka N, Saito T, et al. Antibody responses to the outer membrane protein P6 of non-typeable Haemophilus influenzae and pneumococcal capsular polysaccharides in otitis-prone children. Acta Otolaryngol. 1999;119(6):703–707.
   PubMed Web of Science ®Google Scholar
• Yamanaka N, Faden H. Antibody response to outer membrane protein of nontypeable Haemophilus influenzae in otitis-prone children. J Pediatr. 1993;122(2):212–218.
   PubMed Web of Science ®Google Scholar
• Kodama H, Faden H, Harabuchi Y, et al. Cellular immune response of adenoidal and tonsillar lymphocytes to the P6 outer membrane protein of non-typeable Haemophilus influenzae and its relation to otitis media. Acta Otolaryngol. 1999;119(3):377–383.
   PubMed Web of Science ®Google Scholar
• Abe Y, Murphy TF, Sethi S, et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165(7):967–971.
   PubMed Web of Science ®Google Scholar
• Pradenas GA, Ross BN, Torres AG. Burkholderia cepacia complex vaccines: where do we go from here? Vaccines (Basel). 2016;4(2):10.
   PubMed Web of Science ®Google Scholar